The Wisconsin Alumni Research Foundation (WARF) and Ginkgo Bioworks Inc. have announced a partnership to leverage Ginkgo's proprietary high-throughput combinatorial chimeric antigen receptor (CAR) discovery and screening platform with the aim of discovering next-generation GD2 CAR T-cell therapies.